Aktienanalyse zu Senseonics Holdings Inc (SENS)SENSSenseonics Holdings Inc

Senseonics Holdings, Inc. is a medical technology company focused on the development and manufacturing of glucose monitoring products designed to transform lives in the diabetes community. Its glucose monitoring (CGM) systems Eversense 365 and Eversense E3 include a small sensor inserted completely under the skin that communicates with a smart transmitter worn over the sensor. Its CGM systems are indicated for continually measuring glucose levels for up to 365 days for Eversense 365 and 180 days for Eversense E3 in persons with diabetes age 18 and older. Eversense consists of three primary components: a small sensor inserted subcutaneously under the skin by a healthcare provider; an external removable smart transmitter that receives, assesses and relays data from the sensor and provides vibratory alerts; and a mobile app that receives data from the transmitter and provides real-time glucose readings, alerts and other data the person's mobile device. It operates in the Healthcare sector (INDUSTRIAL INSTRUMENTS FOR MEASUREMENT, DISPLAY, A industry).

Senseonics Holdings Inc is a good buy right now due to its current price of $9.33, which is significantly below the analyst price targets of $14 and $18. The stock has shown a remarkable year-to-date change of +58.40% and a strong gross margin of 59.10% in Q2 2026, indicating robust growth potential. However, the main risk is the negative net income, which was -$36,705,000 in Q2 2026, highlighting ongoing financial challenges.

4 analysts cover SENS: 4 rate it Buy, 0 Hold and 0 Sell. The average price target is 18.70.